Prostate Cancer Clinical Trial
— BETR-PCOfficial title:
Behavioral Exercise TRaining for Medically Underserved Men Undergoing Androgen Deprivation Therapy for Prostate Cancer (BETR-PC)
To refine a remote behavioral exercise training intervention for testing in a larger randomized trial.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | August 31, 2025 |
Est. primary completion date | August 31, 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 41 Years to 85 Years |
Eligibility | Inclusion Criteria: - Be diagnosed with stage II/III/IV prostate cancer - Be currently undergoing treatment with ADT (intermittent or prolonged) - Have completed local curative-intent treatment, including prostatectomy or definitive radiation - Be >40 years of age if non-Hispanic Black or rural dwelling; Otherwise >60 years of age up to 85 - Be willing to give an informed consent and sign a HIPAA authorization form - Not have any hearing or sight impairments that result in the inability to use the telephone or hear normal conversation - Must be able to join an intervention group by personal computer, smartphone or telephone call and should agree to recording of an interview - Be without any serious medical condition that precludes safe participation in an exercise program - Speak English. - Meet protocol definition of medically underserved: which is consider medically underserved patients to be a) older men (>75 years), b) men who live in rural zip code areas, or c) men who identify as being non-Hispanic Black. They may also be at the intersectionality of these groups (i.e., older Black men living in a rural zip code area). |
Country | Name | City | State |
---|---|---|---|
United States | Virginia Commonwealth University | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
Virginia Commonwealth University | NRG Oncology |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasibility of trial by assessing the recruitment rate | The number of participants that enroll | Day 1 | |
Primary | Feasibility of trial by assessing the retention rate | The number of participants that complete greater than 80% of the planned assessments | 12 Weeks | |
Primary | Acceptability of the trial by assessing the retention rate | Number of participants that adhere to and complete the intervention | 12 Weeks | |
Secondary | Physical activity levels using accelerometry (ActivPAL, Actigraph) | An ActivPAL is a small, previously validated thigh-worn device that continuously measures physical activity, sitting time or movement. An Actigraph is a small wrist worn device that continuously measures physical activity intensity (i.e., exercise intensity), sleep time or movement. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Physical activity levels using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). | The average of the scores for participants using the GLTEQ is a 3-item measure used to classify participant's activity levels per week. The Weekly leisure activity score = (9 × Strenuous) + (5 × Moderate) + (3 × Light). The Godin scale score = 24 units or more=active, 14-23 units= moderately active, and less than 14 unites = insufficiently active/ sedentary. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Submaximal exercise capacity assessed with the 6-minute walk test. | Measuring changes in a 6 minute walk distance. The participant has a goal to walk as fast, but safely, as possible without running for a period of 6 minutes. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Physical function as assessed with the short physical performance battery (SPPB). | Short Physical Performance Battery (Short Physical Performance Battery (SPPB) is a battery of 3 tests (standing balance, gait speed and char stands) that are combined to assess overall physical function. Each test is scored on a scale of 1-4 with 4 being reflective of good function and 0 of poor function. Overall scores of 10 or less are reflective of mobility limitations. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Lower body strength assessed with a 30 seconds chair stand test. | Participants will be first asked to stand from a sitting position without using their arms. If they can perform the task, they will then be asked to stand up and sit down as many times as possible in a 30 second period. The greater the number of chair stands the better the lower body strength. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Upper body strength assessed with a grip strength dynamometer. | Grip strength will be assessed using an isometric handgrip dynamometer while the participant is seated with the head facing straight ahead. The elbow should be bent at a 90-degree angle and the wrist should be at the mid-prone position. The participant should exert maximally and quickly (about 1 second) and two trials should be made alternately with each hand, with at least 30 seconds between trials for the same hand (recorded in kilograms). | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Self-efficacy for exercise using the exercise self-efficacy scale (EXSE) to assess socioecological model constructs as multilevel factors associated with physical activity levels and behavioral patterns | The Exercise Self-Efficacy Scale assesses an individual's beliefs in their ability to continue exercising on a three time per week basis at moderate intensities for 40+ minutes per session in the future. For each item, participants indicate their confidence to execute the behavior on a 100-point percentage scale comprised of 10-point increments, ranging from 0% (not at all confident) to 100% (highly confident). Total strength for each measure of self-efficacy is then calculated by summing the confidence ratings and dividing by the total number of items in the scale, resulting in a maximum possible efficacy score of 100. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Social support for exercise scale to assess socioecological model constructs as multilevel factors associated with physical activity levels and behavioral patterns | Assessment of the level of support individuals making health-behavior changes (exercise) felt they were receiving from family and friends.
Family Participation: sum items 11 - 16 and 20 - 23 Family Rewards and Punishment (an optional scale): sum items 17 - 19 Friend Participation: sum items 11 - 16 and 20 - 23 Higher scores reflect more support. |
Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Walk Score to assess socioecological model constructs as multilevel factors associated with physical activity levels and behavioral patterns | Walk Score measures the walkability of any address using a patented system. For each address, Walk Score analyzes hundreds of walking routes to nearby amenities. Points are awarded based on the distance to amenities in each category. Amenities within a 5 minute walk (.25 miles) are given maximum points.
90-100 is a good walk score 70-89 is very walkable 50-69 is somewhat walkable 0-49 is car dependent |
Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using the Functional Assessment of Cancer Therapy-Fatigue scale (FACIT-fatigue) | The FACIT-fatigue scale is a 13-item scale that has been widely used in many studies to assess cancer related fatigue
Scores range from 0-52 with higher scores indicating better quality of life. |
Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess disease specific quality of life (HRQL) using the 42-item Functional Assessment of Cancer Treatment-Prostate (FACT-P) | The FACT-P measure is composed of the FACT-General which assesses four primary HRQOL domains: physical well-being , functional well-being, social well-being, and emotional well-being and an additional component for prostate specific concerns.
Scores range from 0-156 with higher scores reflecting better quality of life |
Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using the the MOS 36-item Short Form Health Survey (SF-36) | The SF-36 is perhaps the most widely used measure of health status and includes domains of vitality and physical function.
The SF-36 has 8 subdomains (physical functioning, role limitations due to physical health, role limitations due to emotional problems, energy/fatigue, emotional well-being, social functioning, pain, general health). Each scale item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively with 100 higher quality of life. |
Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using the Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue Scale 4a | PROMIS - Fatigue is a validated self-report measure of fatigue among patients diagnosed with cancer and higher scores indicate a lower level of fatigue. All scores are on a T-score distribution with a mean of 50 and standard deviation of 10. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using the Patient-Reported Outcomes Measurement Information System (PROMIS) - Physical Function Scale 4a | PROMIS - Physical function is a validated self-report measure of physical function among patients diagnosed with cancer and higher scores indicate better functioning. All scores are on a T-score distribution with a mean of 50 and standard deviation of 10. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using the Patient-Reported Outcomes Measurement Information System (PROMIS) - Anxiety Scale 4a | PROMIS - Anxiety is a validated self-report measure of physical function among patients diagnosed with cancer and higher scores indicate better functioning. All scores are on a T-score distribution with a mean of 50 and standard deviation of 10. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using the Patient-Reported Outcomes Measurement Information System (PROMIS) - Depression Scale 4a | PROMIS - Depression is a validated self-report measure of physical function among patients diagnosed with cancer and higher scores indicate better functioning. All scores are on a T-score distribution with a mean of 50 and standard deviation of 10. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using the Patient-Reported Outcomes Measurement Information System (PROMIS) - Sleep Disturbance Scale 4a | PROMIS - Sleep disturbance is a validated self-report measure of physical function among patients diagnosed with cancer and higher scores indicate better functioning. All scores are on a T-score distribution with a mean of 50 and standard deviation of 10. | Baseline, 8 Weeks, and 12 Weeks | |
Secondary | Assess health-related quality of life (HRQL) using Social Determinants of Health | Social Determinants of Health (SDOH) questionnaire is a self-administered questionnaire used to examine education and income variables in relation to cardiovascular risk. The questionnaire is administered at the baseline visit. We will also ask about difficult paying for basics and experience of racial discrimination at 3- and 6-month follow up visits. | Baseline, 8 Weeks, and 12 Weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |